Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 233

1.

Ezrin immunohistochemical expression in cartilaginous tumours: a useful tool for differential diagnosis between chondroblastic osteosarcoma and chondrosarcoma.

Salas S, de Pinieux G, Gomez-Brouchet A, Larrousserie F, Leroy X, Aubert S, Decouvelaere AV, Giorgi R, Fernandez C, Bouvier C.

Virchows Arch. 2009 Jan;454(1):81-7. doi: 10.1007/s00428-008-0692-8. Epub 2008 Dec 3.

PMID:
19050913
[PubMed - indexed for MEDLINE]
2.

Galectin-1 is a powerful marker to distinguish chondroblastic osteosarcoma and conventional chondrosarcoma.

Gomez-Brouchet A, Mourcin F, Gourraud PA, Bouvier C, De Pinieux G, Le Guelec S, Brousset P, Delisle MB, Schiff C.

Hum Pathol. 2010 Sep;41(9):1220-30. doi: 10.1016/j.humpath.2009.10.028. Epub 2010 Apr 18.

PMID:
20399482
[PubMed - indexed for MEDLINE]
3.

Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas.

Salas S, Bartoli C, Deville JL, Gaudart J, Fina F, Calisti A, Bollini G, Curvale G, Gentet JC, Duffaud F, Figarella-Branger D, Bouvier C.

Virchows Arch. 2007 Dec;451(6):999-1007. Epub 2007 Sep 5.

PMID:
17786474
[PubMed - indexed for MEDLINE]
4.

Ezrin immunohistochemical expression in chondrosarcomas, osteosarcomas and Ewing sarcoma family of tumors.

Machado I, Navarro S, Giner F, Alberghini M, Bertoni F, Llombart-Bosch A.

Virchows Arch. 2010 Jul;457(1):87-9. doi: 10.1007/s00428-010-0940-6. Epub 2010 Jun 16. No abstract available.

PMID:
20552365
[PubMed - indexed for MEDLINE]
5.

Expression of ezrin and metastatic tumor antigen in osteosarcomas of the jaw.

Park HR, Cabrini RL, Araujo ES, Paparella ML, Brandizzi D, Park YK.

Tumori. 2009 Jan-Feb;95(1):81-6.

PMID:
19366061
[PubMed - indexed for MEDLINE]
6.

Histogenesis of clear cell chondrosarcoma. An immunohistochemical study with osteonectin, a non-collagenous structure protein.

Bosse A, Ueda Y, Wuisman P, Jones DB, Vollmer E, Roessner A.

J Cancer Res Clin Oncol. 1991;117(1):43-9.

PMID:
1997469
[PubMed - indexed for MEDLINE]
7.

Ezrin in osteosarcoma: comparison between conventional high-grade and central low-grade osteosarcoma.

Park HR, Jung WW, Bacchini P, Bertoni F, Kim YW, Park YK.

Pathol Res Pract. 2006;202(7):509-15. Epub 2006 May 3.

PMID:
16677779
[PubMed - indexed for MEDLINE]
8.

Periosteal osteosarcoma and parosteal chondrosarcoma evaluated by double immunohistochemical staining. Report of 2 cases.

Chano T, Matsumoto K, Ishizawa M, Morimoto S, Hukuda S, Okabe H.

Acta Orthop Scand. 1994 Jun;65(3):355-8.

PMID:
7518993
[PubMed - indexed for MEDLINE]
9.

Ezrin expression predicts survival in stage IIB osteosarcomas.

Kim MS, Song WS, Cho WH, Lee SY, Jeon DG.

Clin Orthop Relat Res. 2007 Jun;459:229-36.

PMID:
17353802
[PubMed - indexed for MEDLINE]
10.

Galectin-1 (GAL-1) expression is a useful tool to differentiate between small cell osteosarcoma and Ewing sarcoma.

Machado I, López Guerrero JA, Navarro S, Mayordomo E, Scotlandi K, Picci P, Llombart-Bosch A.

Virchows Arch. 2013 Jun;462(6):665-71. doi: 10.1007/s00428-013-1423-3. Epub 2013 May 17.

PMID:
23681112
[PubMed - indexed for MEDLINE]
11.

Phosphorylated ezrin is located in the nucleus of the osteosarcoma cell.

Di Cristofano C, Leopizzi M, Miraglia A, Sardella B, Moretti V, Ferrara A, Petrozza V, Della Rocca C.

Mod Pathol. 2010 Jul;23(7):1012-20. doi: 10.1038/modpathol.2010.77. Epub 2010 Mar 26.

PMID:
20348881
[PubMed - indexed for MEDLINE]
Free Article
12.

Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma.

Ferrari S, Zanella L, Alberghini M, Palmerini E, Staals E, Bacchini P.

Pediatr Blood Cancer. 2008 Apr;50(4):752-6.

PMID:
17886294
[PubMed - indexed for MEDLINE]
13.

Expression change of ezrin as a prognostic factor in primary osteosarcoma.

Wang YF, Shen JN, Xie XB, Wang J, Huang G.

Med Oncol. 2011 Dec;28 Suppl 1:S636-43. doi: 10.1007/s12032-010-9684-z. Epub 2010 Sep 22.

PMID:
20859706
[PubMed - indexed for MEDLINE]
14.

The impact of osteonectin for differential diagnosis of osteogenic bone tumors: an immunohistochemical and in situ hybridization approach.

Park YK, Yang MH, Park HR.

Skeletal Radiol. 1996 Jan;25(1):13-7.

PMID:
8717113
[PubMed - indexed for MEDLINE]
15.

Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors.

Naka T, Iwamoto Y, Shinohara N, Ushijima M, Chuman H, Tsuneyoshi M.

Mod Pathol. 1997 Aug;10(8):832-8.

PMID:
9267827
[PubMed - indexed for MEDLINE]
16.

Dedifferentiated peripheral chondrosarcomas: regulation of EXT-downstream molecules and differentiation-related genes.

Rozeman LB, de Bruijn IH, Bacchini P, Staals EL, Bertoni F, Bovée JV, Hogendoorn PC.

Mod Pathol. 2009 Nov;22(11):1489-98. doi: 10.1038/modpathol.2009.120. Epub 2009 Sep 4.

PMID:
19734846
[PubMed - indexed for MEDLINE]
Free Article
17.

ERG expression in chondrogenic bone and soft tissue tumours.

Shon W, Folpe AL, Fritchie KJ.

J Clin Pathol. 2015 Feb;68(2):125-9. doi: 10.1136/jclinpath-2014-202601. Epub 2014 Nov 5.

PMID:
25378537
[PubMed - in process]
18.

Osteosarcomas and chondrosarcomas of the jaws: immunohistochemical correlations.

Regezi JA, Zarbo RJ, McClatchey KD, Courtney RM, Crissman JD.

Oral Surg Oral Med Oral Pathol. 1987 Sep;64(3):302-7.

PMID:
2443891
[PubMed - indexed for MEDLINE]
19.

Histological grading and morphometric analysis of cartilaginous tumours.

Ishida T, Kikuchi F, Machinami R.

Virchows Arch A Pathol Anat Histopathol. 1991;418(2):149-55.

PMID:
1899957
[PubMed - indexed for MEDLINE]
20.

Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumours of the skeleton.

Franchi A, Calzolari A, Zampi G.

Virchows Arch. 1998 Jun;432(6):515-9.

PMID:
9672192
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk